June 27, 2025

Weight Loss Drugs, Heavier Implications

New guidance positions GLP-1 and GLP-1/GIP therapies as frontline options for long-term weight management—with profound implications for cardiovascular outcomes, access equity, and chronic disease care.

Conexiant

June 18, 2025

NCCN Clinical Practice Guidelines in Oncology: 2025 Updates

The National Comprehensive Cancer Network (NCCN) released its first set of Clinical Practice Guidelines in Oncology (NCCN Guidelines®) in 1996, covering eight tumor types. Today, guidelines are availa...

The ASCO Post

June 17, 2025

Proposed Budget Cuts to Medicaid May Result in More Than 16,500 Medically Preventable Deaths Annually

The enactment of the proposed budget bill making its way through Congress, which includes major cuts to Medicaid, could increase the number of uninsured Americans by 7.6 million and the number of medi...

The ASCO Post

June 13, 2025

Weight Loss Drugs Show Promise for Heart Failure

ACC statement highlights semaglutide and tirzepatide as therapies associated with improved symptoms and functional capacity in patients with heart failure with preserved ejection fraction and obesity.

Conexiant

July 12, 2023

Changing How Immune Checkpoint Inhibitors Are Delivered Could Reduce Costs by 14%, Study Finds

Investigators have found that millions of dollars could be saved annually across the Veterans Health Administration by reconsidering how immune checkpoint inhibitors are delivered, according to a new ...

The ASCO Post

November 13, 2024

Is COPD Set to Affect 600M Globally?

GOLD 2025 highlights new pathways and advanced COPD therapies like ensifentrine and dupilumab to reduce exacerbations and address emerging COPD phenotypes.

Conexiant

May 07, 2025

Cystic Fibrosis: New Evidence-Based Guidelines for Newborn Screening

New Cystic Fibrosis Foundation guidelines aim to improve consistency, equity, and accuracy in CF newborn screening nationwide.

Conexiant

October 31, 2023

Clinical Trial Evaluates New Targeted Therapy for KRAS G12c-mutant Lung Cancer and Other Malignancies

A phase 1/1b, open-label clinical trial underway at Roswell Park Comprehensive Cancer Center is taking a new approach to targeting KRAS G12C, the most common mutation in non-small cell lung cancer (NSCLC) and one that is sometimes present in colorectal cancer, pancreatic ductal adenocarcinoma and other solid tumors.

Roswell Park Comprehensive Cancer Center

August 28, 2023

Register Now! Mount Sinai Respiratory Institute Symposium

The Mount Sinai Respiratory Institutes is offering a 2 day comprehensive course on advanced topics in pulmonary medicine, directed toward community pulmonologists, advanced practice NP and PA providers as well primary care physicians.

Mount Sinai New York